Cullgen Inc.

Cullgen Inc., founded in 2018, is at the forefront of the biopharmaceutical sector with its pioneering slogan: "Powering protein degradation for tomorrow's medicines." The company is headquartered in the United States and operates in the Biotechnology and Pharmaceutical industries.

Leveraging its proprietary uSMITE™ technology, Cullgen addresses the challenge of intracellular disease targets. The technology taps into the body's own protein disposal mechanism to degrade disease-causing proteins, including those undruggable by traditional therapies. This innovative approach has potential implications for a myriad of diseases.

Recently, Cullgen secured a $35.00M Series C investment on 08 May 2023, attracting investors like 无锡市金融投资有限责任公司, Sincere Capital, Voyagers Capital, GNI Japan, and AstraZeneca-CICC Venture Capital. This financial backing highlights the confidence in Cullgen's disruptive platform and its promise in transforming therapeutic avenues.